Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental cell therapy takes on aggressive childhood leukemia

NCT ID NCT06934382

Recruiting now Disease control Sponsor: Stephan Grupp MD PhD Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 25 times

Summary

This early-phase study tests BEAM-201, a type of immune cell therapy made from donor cells, in children and young adults up to age 29 with T-cell acute lymphoblastic leukemia or lymphoma that has returned or not responded to standard treatments. The goal is to find a safe dose and see if the therapy can shrink or eliminate the cancer. Participants will be closely monitored for side effects and treatment response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA